155535-20-9

Usage

Uses

Used in Chemical Production:
2-chloro-5,6,7,8-tetrahydroquinoxaline is used as an intermediate in the synthesis of more complex chemicals. Its unique structure allows it to be a valuable building block in the creation of various compounds, contributing to the diversity of chemical products.
Used in Research Processes:
2-chloro-5,6,7,8-tetrahydroquinoxaline is used as a research chemical, facilitating the study of quinoxaline derivatives and their potential applications in various fields. Its role in research helps to expand the understanding of chemical reactions and the properties of related compounds.
Used in Pharmaceutical Industry:
2-chloro-5,6,7,8-tetrahydroquinoxaline is used as a starting material for the development of new pharmaceutical compounds. Its presence in the synthesis process can lead to the creation of novel drugs with potential therapeutic applications, making it an important component in the advancement of medicine.
Used in Material Science:
2-chloro-5,6,7,8-tetrahydroquinoxaline is used as a component in the development of new materials with specific properties. Its incorporation into material formulations can result in materials with unique characteristics, such as improved stability or enhanced reactivity, which can be beneficial in various industrial applications.

Upstream product

• 27579-58-4 5,6,7,8-tetrahydro-2(1H)-quinoxalinone 
• 765-87-7 cyclohexane-1,2-dione 

Relevant academic research and scientific papers

RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS

The present invention concerns compounds of formula prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof wherein -a=a-a=a- represents a radical of formula -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; - CH=CH-CH=N-; wherein each hydrogen atom may optionally be substituted; Q is a radical of formula wherein Alk is C1-6alkanediyl; Y is a bivalent radical of formula -NR- or -CH(NRR)-; X is NR, S, S(=O), S(=O)2, O, CH2, C(=O), CH(=CH2), CH(OH), CH(CH3), CH(OCH3), CH(SCH3), CH(NRR), CH2-NR or NR-CH2; X is a direct bond, CH2, C(=O), NR, C1-4alkyl-NR, NR-C1-4alkyl; v is 2 or 3; and whereby each hydrogen in Alk and in (b-6), (b-7) and (b-8), may optionally be replaced by R; provided that when R is hydroxy or C1-6alkyloxy, then R can not replace a hydrogen atom in the alpha position relative to a nitrogen atom; G is a direct bond or optionally substituted C1-10alkanediyl; R is an optionally substituted bicyclic heterocycle; R is hydrogen, formyl, C1-6 alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C3-7cycloalkyl or C1-10alkyl substituted with N(R)2 and optionally with another substituent; R is hydrogen, hydroxy, C1-6alkyl, C1-6alkyloxy, arylC1-6alkyl or arylC1-6alkyloxy; R is hydrogen, C1-6alkyl or arylC1-6alkyl; R, R, R and R are hydrogen or C1-6alkyl; or R and R, or R and R taken together from a bivalent radical of formula -(CH2)s- wherein s is 4 or 5; R is hydrogen, C1-4alkyl, formyl, hydroxyC1-6alkyl, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; aryl is optionally substituted phenyl; Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; as respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and their use as a medicine.

Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands

The present invention encompasses structures of the formula: STR1 and the pharmaceutically acceptable non-toxic salts thereof wherein: STR2 where W represents an aromatic group substituted with various organic and inorganic substituents;X, Y are hydrogen, halogen, hydroxy or amino with the proviso that at least X or Y is hydroxy;A, B C, and D, represent nitrogen or a carbon atom substituted with various organic and inorganic substituents;E represents oxygen, sulfur or substituted nitrogen;R 3, R 4, R 12, and R 13 are variables representing various organic and inorganic substituents; andn is 0, 1, or 2.